Partner News | Published: Thursday, March 26, 2020
BioTelemetry, Inc. (NASDAQ:BEAT), a leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced the activation of an expanded service using its Mobile Cardiac Outpatient Telemetry (MCOT™) to monitor life-threatening QT prolongation in COVID-19 patients. As a reminder, MCOT is the most accurate and studied arrhythmia monitoring detection system in the market. It provides up to 30 days of near real time monitoring without patients needing to leave their homes. The Company is currently implementing this COVID-19 monitoring initiative in several major institutions and physicians have already started using this service.